Retatrutide Research & Authoritative Sources
This page is an independently organized research library designed to help readers review original and authoritative information about retatrutide (LY3437943). TryTrutide links directly to scientific journals, clinical-trial registries, manufacturer research materials, government resources, and recognized scientific publications. We are not affiliated with, endorsed by, or sponsored by any of the organizations listed below.
Retatrutide remains an investigational drug under clinical development. It has not currently received FDA approval. Clinical trials continue to evaluate its safety, efficacy, dosing, and potential therapeutic uses. For current trial status, consult ClinicalTrials.gov, Eli Lilly's pipeline, or TryTrutide's FDA & Regulation page.
Frequently Asked Questions About Retatrutide
What is retatrutide?
Retatrutide, also known as LY3437943, is an investigational once-weekly triple hormone receptor agonist being developed by Eli Lilly and Company. It activates receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon.
What is LY3437943?
LY3437943 is Eli Lilly's internal compound designation for retatrutide. Both names refer to the same investigational molecule.
What receptors does retatrutide target?
Retatrutide targets three receptors: the GIP receptor, the GLP-1 receptor, and the glucagon receptor. This triple agonism distinguishes it from dual agonists such as tirzepatide (GIP + GLP-1 only).
Is retatrutide a GLP-1 drug?
Retatrutide includes GLP-1 receptor agonism as one of its three mechanisms, but it is more precisely classified as a triple hormone receptor agonist. Calling it only a "GLP-1 drug" understates its mechanism.
What is a triple agonist?
A triple agonist is a drug that activates three distinct hormone receptors simultaneously. In retatrutide's case, those are the GIP, GLP-1, and glucagon receptors.
Is retatrutide FDA-approved?
No. Retatrutide is currently investigational and is not FDA-approved. It is available only through authorized clinical trials.
Who developed retatrutide?
Retatrutide is being developed by Eli Lilly and Company. It is not affiliated with any compounding pharmacy, research-chemical vendor, or online peptide supplier.
What clinical trials are studying retatrutide?
The TRIUMPH program (TRIUMPH-1 through TRIUMPH-9 and TRIUMPH-Outcomes) and the TRANSCEND program (TRANSCEND-T2D-2 and TRANSCEND-T2D-3) are the primary Phase 3 trial series. See the ClinicalTrials.gov section below for direct registry links.
Where can retatrutide research be found?
Primary sources include ClinicalTrials.gov, PubMed, the New England Journal of Medicine, Nature Medicine, Cell Discovery, and Eli Lilly's investor and research pages. All are linked directly on this page.
Eli Lilly Retatrutide Research
Manufacturer-sponsored sources. Lilly identifies retatrutide as LY3437943 and describes it as a GIP, GLP-1, and glucagon receptor triagonist being studied across several cardiometabolic indications. These pages are produced by the drug's developer and should be read as manufacturer sources.
What to Know About Retatrutide
Eli Lilly's primary educational overview of retatrutide, identifying the compound as LY3437943 and describing its development as a GIP, GLP-1, and glucagon receptor triagonist across cardiometabolic indications.
Clinical Development Pipeline
Lilly's research and development pipeline page, which lists retatrutide (LY3437943) among its investigational compounds and indicates the therapeutic areas under study.
TRIUMPH Phase 3 Results: Substantial Improvements
Lilly's investor-relations announcement reporting Phase 3 TRIUMPH trial topline results, including weight loss and cardiometabolic outcomes data.
Retatrutide Successful in Two Additional Phase 3 Trials
Lilly's announcement of positive topline results from two additional TRIUMPH Phase 3 trials, covering additional populations and endpoints.
Peer-Reviewed Retatrutide Research
Original research published in peer-reviewed scientific journals. These represent the highest-quality published evidence on retatrutide's mechanism, efficacy, and safety.
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
This randomized Phase 2 study evaluated retatrutide in adults with obesity or overweight, examining efficacy across dose levels, safety profile, adverse events, and dose-response relationships. It represents the primary peer-reviewed Phase 2 efficacy dataset.
LY3437943, a novel triple GIP, GLP-1 and glucagon receptor agonist in people with type 2 diabetes
An earlier Phase 1b clinical study evaluating LY3437943 in people with type 2 diabetes, examining safety, tolerability, pharmacokinetics, and preliminary glycemic effects.
Nature Portfolio & Scientific Reviews
Peer-reviewed research and scientific reviews published in Nature-family journals, covering liver disease, structural biology, and the broader obesity-pharmacotherapy pipeline.
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease
This Phase 2a substudy examined changes in liver fat content among participants with metabolic dysfunction-associated steatotic liver disease (MASLD), providing evidence on retatrutide's potential hepatic effects.
Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide
Structural biology research examining how retatrutide interacts with GLP-1, GIP, and glucagon receptors at the molecular level, providing mechanistic insight into its triple agonist activity.
What is the pipeline for future medications for obesity?
A broader obesity-pharmacotherapy review that discusses retatrutide within the developing anti-obesity medication pipeline, providing context for where retatrutide sits among next-generation agents.
ClinicalTrials.gov — Retatrutide Trial Registry
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies. It provides authoritative, continuously updated information on trial status, eligibility criteria, enrollment, and results. Links below go directly to individual trial records — not the ClinicalTrials.gov homepage. Trial status shown here reflects the registry at the time of last review; consult the live registry link for current status.
Obesity or overweight, including osteoarthritis and obstructive sleep apnea subsets.
View on ClinicalTrials.gov →Retatrutide compared with tirzepatide in adults with obesity.
View on ClinicalTrials.gov →Cardiovascular and kidney outcomes in adults living with obesity.
View on ClinicalTrials.gov →Retatrutide compared with semaglutide in adults with type 2 diabetes.
View on ClinicalTrials.gov →Type 2 diabetes with moderate or severe renal impairment.
View on ClinicalTrials.gov →Not all trials listed above are completed. For current enrollment status, primary completion dates, and results, consult the live ClinicalTrials.gov record for each trial. See also TryTrutide's Clinical Trials Center and Find a Retatrutide Clinical Trial.
General Reference
Supplementary general-reference sources. These are not primary scientific sources and should not be used as the sole basis for medical or clinical decisions.
Wikipedia — Retatrutide
Wikipedia provides an independently edited general overview of retatrutide and references additional scientific literature. It is useful as a starting point for general orientation but should be supplemented with peer-reviewed and primary sources for any clinical or research purpose.
Retatrutide Terminology
Plain-English explanations of the scientific and clinical terms used in retatrutide research. Accurate terminology helps readers evaluate sources and understand what claims are actually being made.